BioViva

BioViva was founded in 2015. The CEO, Elizabeth Parrish, started the company by becoming the first person in human history to take gene therapies associated with lengthening lifespans in model organism, she appeared at WIRED Health 2017 in London to discuss BioViva's testing of gene therapies targeting hallmarks of the ageing process. She stated, "The company was built essentially to prove these therapies work or not." Since then the company has gone into research and development and patented AAV based gene therapies and launched a new gene therapy platform with CMV as the vector. Parrish stated there was no other way to protect people's rights to new medicine in a recent talk in India at the Synapse Conference. Parrish's decision to be 'patient zero' and test the company's technology on herself in a personalized N=1 study was a response to her son's diagnosis of Type 1 Diabetes. After finding no curative course Parrish looked into genetics. She claims that every gene BioViva targets will also treat a childhood disease. Dr. Lawrence Altman, author of Who Goes First?